Skip to main content
. 2018 Jan 2;13(1):e0190219. doi: 10.1371/journal.pone.0190219

Table 1. Demographic characteristics of the study population with and without HP therapy.

Characteristics Group A Patients with HP therapy (≤ 365 days) (n = 3164) Group B Patients without HP therapy (n = 3164) P value
N % N %
HP therapy*
First 3141 99.27% -- --
 HP4+HP3+HP1 3081 98.09% -- --
 HP4+HP3+HP2 2 0.06% -- --
 HP5+HP3+HP1 101 3.22% -- --
 HP5+HP3+HP2 1 0.03% -- --
Second 24 0.76% -- --
 HP4+HP6+HP8+HP2 0 0.00% -- --
 HP5+HP6+HP8+HP2 0 0.00% -- --
 HP4+HP7+HP1 19 79.17% -- --
 HP5+HP7+HP1 9 37.50% -- --
Age, years old (mean ± SD) 47.73±14.24 47.73±14.24 1.0000
Age_Class1
< 49 1821 57.55% 1821 57.55% 0.9951
50–59 713 22.53% 713 22.53%
60–69 353 11.16% 354 11.19%
≥ 70 277 8.75% 276 8.72%
Age_Class2
< 65 2741 86.63% 2741 86.63% 1.0000
≥ 65 423 13.37% 423 13.37%
Gender
Male 1895 59.89% 1896 59.92% 0.9795
Female 1269 40.11% 1268 40.08%
Charlson score
0 2441 77.15% 2441 77.15% 0.9998
1 649 20.51% 648 20.48%
2 69 2.18% 70 2.21%
≥ 3 5 0.16% 5 0.16%
Charlson score (mean ± SD) 0.25±0.49 0.25±0.49 1.0000
Charlson comorbidity
 Dementia 5 0.16% 5 0.16% 1.0000
 Pulmonary disease 95 3.00% 95 3.00% 1.0000
 Connective tissue disorder 14 0.44% 14 0.44% 1.0000
 Peptic ulcer 535 16.91% 535 16.91% 1.0000
 Liver disease 131 4.14% 130 4.11% 1.0000
 Paraplegia 0 0.00% 1 0.03% 0.3173
 Renal disease 11 0.35% 11 0.35% 1.0000
Comorbidity
 Hypertension 286 9.04% 287 9.07% 0.9651
 Hyperlipidemia 115 3.63% 115 3.63% 1.0000

Abbreviations: HP, Helicobacter pylori; HIV, human immunodificiency virus

*HP1 = Amoxicillin, HP2 = Metronidazole, HP3 = Clarithromycin, HP4 = PPI, HP5 = H2 blockers, HP6 = Bismuth, HP7 = Levofloxacin, HP8 = Tetracycline